The Forth Bridge at sunrise, seen from above the Firth of Forth

Bridging innovation with global opportunity

Founded 2014 | St Andrews, Scotland

Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving life.

Eos is a trusted link between non-specialist investors and knowledge intensive science and technology companies.

The Eos team on the steps of a stone building in St Andrews

Deep roots in Scotland,
with a global perspective.

Motivation for all parties is commensurate financial returns for early-stage patient capital allocation, in businesses that are creating positive impact.

Eos works in long-term partnerships with family offices, individuals, companies and institutional investors.

The portfolio is split between

Quality of life

  • Disease diagnostics
  • Prevention
  • Treatment

Environmental sustainability

  • Food and water security
  • Addressing pollution
  • Clean energy
  • Sustainable infrastructure

Meet some of our Founders & CEOs

Naturbeads

Biodegradable, sustainable and cost competitive cellulose microparticles to replace plastic microbeads

Eos first invested: June, 2022

Naturbeads

Eos Portfolio

Meet our inspiring founders. Companies are defined by people and their performance.

Bioliberty
Bioliberty
Bioliberty creates soft robotics technology to provide social care services to improve patient outcomes.Visit site
Biotangents
CamGene Therapeutics
Carcinotech
Carcinotech
Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.Visit site
Chemify
Chemify
Chemify is building the digital chemistry infrastructure to enable worldwide access to any desired compound instantly and on-demandVisit site
Concinnity Genetics
Cumulus Oncology
Cumulus Oncology
Europes first cancer drug accelerator. Finding assets, creating spin-outs, commercialising cancer therapies.Visit site
Dxcover
Dxcover
Offers a revolutionary spectroscopic liquid biopsy with artificial intelligence for the early detection of cancer and other diseases.Visit site
EnsiliTech
GM Flow
GM Flow
Formed in 2014 to offer Adjusta-Cone® as the world’s first fully adjustable differential pressure cone meter for natural gas.Visit site
ILC Therapeutics
Laverock Therapeutics
Laverock Therapeutics
Laverock Therapeutics is developing a unique gene silencing platform for the creation of programmable advanced therapies.Visit site
Nami Surgical
Naturbeads
Naturbeads
Biodegradable, sustainable and cost competitive cellulose microparticles to replace plastic microbeadsVisit site
Neupulse
Novosound
Novosound
An award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.Visit site
Silverbac
Silverbac
Novel Technologies has developed a technology where pure silver particles are incorporated into fibres as a antimicrobial coating for paints and textiles in a way that is ecologically sound and non-toxic to humans.Visit site
Penrhos Bio
Penrhos Bio
Penrhos Bio offers Remora technology, inspired by nature, that protects against bacteria, fungi, and algae, to provide self-cleaning surfaces.Visit site
Wobble Genomics
Wobble Genomics
Specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.Visit site

Eos has a long-term partnership approach with like-minded individuals, family offices & companies.

The funding model works across seed & growth stages, on a managed or discretionary basis. Investment relationships range from multistage and multiyear through to the original angel syndicate. Offers S/EIS UK tax relief for relevant investors when available.

Who are you?

  • I am seeking investment
  • Eos manages

    Innovation Fund

    • Seed round investments
    • Annual close (Q4), minimum of £25k with a typical range of £100k-£500k
    • 5-8 investments per year
    • Each ‘vintage’ is separate, but most investors invest each year
    Get in touch
  • Eos arranges, members make decisions

    Venture Partners

    • For growth rounds & Series A+
    • Opportunities presented on ad-hoc basis
    • Minimum of £25k with typical range of £100k-£1M+ in any one deal
    • Opportunities normally grown out of Innovation Fund, but occasionally from wider market
    Get in touch
  • Eos arranges, members make decisions

    Angel Syndicate

    • Initial equity investment & follow-ons within existing portfolio
    • Minimum investment of £5k per investment
    • The founding pillar of Eos, accounting for c. 13% of investments per annum
    • Meetings happen virtually on a monthly basis & in-person each quarter
    Get in touch
Ticket size per investmentMinimum and typical range, as stated for each route
  • Innovation FundSeedMinimum £25k, typical £100k to £500k.
  • Venture PartnersGrowth & Series A+Minimum £25k, typical £100k to £1M+.
  • Angel SyndicateInitial & follow-onMinimum £5k.

Our Partners

  • UK Business Angels Association member
  • Enterprise Investment Scheme Association
  • Working with British Business Bank

Team

The Eos team is made up of founders, scientists, record breakers, industry leaders, and government advisors.

Meet the entire Eos team
Pathways Pledge partner

Eos is committed to building a diverse and inclusive organisation through the investments we make, our investors, and our team.

Amongst the first signatories to the Pathways Pledge our actions include hosting events to improve accessibility of investment, as well as ensuring a diverse selection panel.

Get in touch

Eos Advisory LLP,
Kinburn Castle,
Doubledykes Road,
St Andrews, KY16 9DR
enquiries@eos-advisory.com